MetLife Plunges 2.3%: A Sudden Descent from the 99.49 Peak

Summary
• MetLife (MET) closes at $97.605, marking a sharp intraday decline of -2.346% from the previous close.

• The stock opened at $99.49, matched the intraday high, but failed to hold gains, sliding to a low of $97.22.

• Technical indicators flash caution: RSI sits at 73.22 (overbought), while the price has retreated from the upper Bollinger Band of $99.17.

• Sector headwinds loom as Life & Health Insurance faces scrutiny over Medicaid cuts and rising healthcare costs.

MetLife experienced a violent reversal today, shedding nearly $2.40 per share as buyer interest evaporated after the opening bell. Despite a strong 52-week high of $100.93 and a robust long-term bullish trend, the stock’s failure to sustain levels above $99 signals significant distribution pressure. The move coincides with broader sector anxiety regarding federal funding and policy shifts, creating a perfect storm for profit-taking.
Sector Headwinds and Technical Exhaustion Drive Sell-Off
The primary driver behind MetLife’s -2.346% decline is a confluence of sector-specific regulatory fears and technical overextension. News regarding federal funding cuts to medical research and steep reductions to Medicaid has cast a shadow over the Life & Health Insurance sector, with experts warning of potential hospital closures and rural community impacts. This macro-environmental pressure has triggered a reassessment of insurer valuations. Simultaneously, MetLife’s technical setup was fragile; the stock had rallied to near its 52-week high of $100.93, pushing the RSI into overbought territory at 73.22. The combination of profit-taking by technical traders and fundamental concerns over Medicaid policy created a liquidity vacuum, allowing the stock to slide from its opening high of $99.49 down to $97.22 without meaningful bid support.